Fig. 6.

Nano-com achieves a superior effect on Sar-R head and neck tumor growth than monotherapy in orthotopic xenograft mice. a The flowchart of drug treatment process. b Tumor development and progression in mice receiving different treatments monitored by examining bioluminescence in the Xenogen IVIS-200 In Vivo imaging system on Day 21. The representative images and quantitative data (n = 5) were shown in the left and right panels, respectively. c The representative images showing the size of tongue tumors in mice receiving the indicated treatment. d The average weight of tongue and body in different treatment groups. e Histology examination of tissues taken from mouse major organs (heart, intestine, kidney, liver, lung and spleen) at the endpoint of each treatment. Nano-sar: saracitinib-loaded NPs; Nano-cap: capivasertib-loaded NPs; Com: free saracatinib/capivasertib combination; Nano-com: the saracatinib/capivasertib co-delivery NPs. *p < 0.05; **p < 0.01